The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland

被引:5
|
作者
Ward, Thomas [1 ,2 ]
Brown, Tray [1 ]
Lewis, Ruth D. [1 ]
Kliess, Melodi Kosaner [1 ]
de Arellano, Antonio Ramirez [3 ]
Quinn, Carol M. [4 ]
机构
[1] Hlth Econ & Outcomes Res Ltd, Rhymney House,Unit A,Cardiff Gate Business Pk, Cardiff, Wales
[2] Univ Exeter, Coll Med & Hlth, Hlth Econ Grp, Exeter, Devon, England
[3] HEOR, Vifor Pharma Grp, Glattbrugg, Switzerland
[4] Vifor Pharma Grp, Dept Med, Glattbrugg, Switzerland
关键词
SERUM POTASSIUM LEVELS; SODIUM POLYSTYRENE SULFONATE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR EVENTS; HEMODIALYSIS-PATIENTS; INTESTINAL NECROSIS; CLINICAL-OUTCOMES; MORTALITY; ASSOCIATION; CKD;
D O I
10.1007/s41669-022-00357-z
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background and Objective Hyperkalaemia can be a life-threatening condition, particularly in patients with advanced chronic kidney disease with and without heart failure. Renin-angiotensin-aldosterone system inhibitor therapy offers cardiorenal protection in chronic kidney disease and heart failure; however, it may also cause hyperkalaemia subsequently resulting in down-titration or discontinuation of treatment. Hence, there is an unmet need for hyperkalaemia treatment in patients with chronic kidney disease with and without heart failure to enable renin-angiotensin-aldosterone system inhibitor use in this patient population. In this study, we develop a de novo disease progression and cost-effectiveness model to evaluate the clinical and economic outcomes associated with the use of patiromer for the treatment of hyperkalaemia in patients with chronic kidney disease with and without heart failure. Methods A Markov model was developed using data from the OPAL-HK trial to assess the health economic impact of patiromer therapy in comparison to standard of care in controlling hyperkalaemia in patients with advanced chronic kidney disease with and without heart failure in the Irish setting. The model was designed to predict the natural history of chronic kidney disease and heart failure and quantify the costs and benefits associated with the use of patiromer for hyperkalaemia management over a lifetime horizon from a payer perspective. Results Treatment with patiromer was associated with an increase in discounted life-years (8.62 vs 8.37) and an increase in discounted quality-adjusted life-years (6.15 vs 5.95). Incremental discounted costs were predicted at (sic)4979 per patient, with an incremental cost-effectiveness ratio of (sic)25,719 per quality-adjusted life-year gained. Patients remained taking patiromer treatment for an average of 7.7 months, with treatment associated with reductions in the overall clinical event incidence and a delay in chronic kidney disease progression. Furthermore, patiromer was associated with lower overall rates of hospitalisation, major adverse cardiovascular events, dialysis, renin-angiotensin-aldosterone system inhibitor discontinuation episodes and renin-angiotensin-aldosterone system inhibitor down-titration episodes. At a willingness-to-pay threshold of (sic)45,000 per quality-adjusted life-year in Ireland, treatment with patiromer was estimated to have a 100% chance of cost effectiveness compared with standard of care. Conclusions This study has demonstrated an economic case for the reimbursement of patiromer for the treatment of hyperkalaemia in patients with chronic kidney disease with and without heart failure in Ireland. Patiromer was estimated to improve life expectancy and quality-adjusted life expectancy, whilst incurring marginal additional costs when compared with current standard of care. Results are predominantly attributed to the ability of patiromer to enable the continuation of renin-angiotensin-aldosterone system inhibitor treatment whilst also reducing potassium levels.
引用
收藏
页码:757 / 771
页数:15
相关论文
共 50 条
  • [21] MANAGEMENT OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH AND WITHOUT CONGESTIVE HEART FAILURE
    Faisa, Manthodi
    Burke, Peter
    Zhang, Wei
    Bowen, James
    Jurkovitz, Claudine
    Israni, Rubeen
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2012, 59 (04) : A34 - A34
  • [22] Practical guidance for the use of potassium binders in the management of hyperkalaemia in patients with heart failure and/or chronic kidney disease
    Campbell, Patricia
    McKeveney, Paul
    Donegan, Kay
    Ataliotis, Charlie
    Patton, Carol
    Mullan, Robert
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2021, 82 (04)
  • [23] DEVELOPMENT OF A MORTALITY RISK PREDICTION TOOL FOR PATIENTS WITH HEART FAILURE OR CHRONIC KIDNEY DISEASE AT RISK OF HYPERKALAEMIA
    Bennett, H.
    McEwan, P.
    Ayoubkhani, D.
    Evans, M.
    Qin, L.
    Kim, K.
    Palaka, E.
    VALUE IN HEALTH, 2017, 20 (09) : A682 - A682
  • [24] Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life
    Esteban-Fernandez, Alberto
    Cortes, Carolina Ortiz
    Lopez-Fernandez, Silvia
    Mayoral, Alejandro Recio
    Camacho Jurado, Francisco Javier
    Otero, Ines Gomez
    Molina, Maria
    Bonet, Luis Almenar
    Lopez-Vilella, Raquel
    ESC HEART FAILURE, 2022, 9 (05): : 3071 - 3078
  • [25] Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
    Mark Bounthavong
    Javed Butler
    Chantal M. Dolan
    Jeffrey D. Dunn
    Kathryn A. Fisher
    Nina Oestreicher
    Bertram Pitt
    Paul J. Hauptman
    David L. Veenstra
    PharmacoEconomics, 2019, 37 : 1071 - 1071
  • [26] ASSESSING THE COST-EFFECTIVENESS OF PATIROMER PLUS SPIRONOLACTONE THERAPY IN HEART FAILURE PATIENTS WITH HYPERKALEMIA
    Bounthavong, M.
    Butler, J.
    Dolan, C. M.
    Dunn, J. D.
    Fisher, K. A.
    Oestreicher, N.
    Pitt, B.
    Hauptman, P. J.
    Veenstra, D. L.
    VALUE IN HEALTH, 2017, 20 (05) : A271 - A271
  • [27] Impact of treatment of hyperkalaemia on quality of life: design of a prospective observational cohort study of long-term management of hyperkalaemia in patients with chronic kidney disease or chronic heart failure in Japan
    Shibagaki, Yugo
    Yamazaki, Hajime
    Wakita, Takafumi
    Ware, John E.
    Wang, Jui
    Onishi, Yoshihiro
    Yajima, Toshitaka
    Sada, Ken-Ei
    Yamamoto, Yosuke
    Fukuhara, Shunichi
    BMJ OPEN, 2023, 13 (12):
  • [28] Cost Effectiveness of Eplerenone in Patients with Chronic Heart Failure
    Zanfina Ademi
    Kumar Pasupathi
    Henry Krum
    Danny Liew
    American Journal of Cardiovascular Drugs, 2014, 14 : 209 - 216
  • [29] Cost Effectiveness of Eplerenone in Patients with Chronic Heart Failure
    Ademi, Zanfina
    Pasupathi, Kumar
    Krum, Henry
    Liew, Danny
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2014, 14 (03) : 209 - 216
  • [30] Diabetes mellitus has the prognostic impact in chronic heart failure patients with chronic kidney disease but not without chronic kidney disease
    Fukunami, MMasatake
    Yamada, T.
    Morita, T.
    Furukawa, Y.
    Tamaki, S.
    Iwasaki, Y.
    Kawasaki, M.
    Kikuchi, A.
    Kondoh, T.
    EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 : 322 - 322